Simplify Logo
GSK

GSK

Develops medicines, vaccines, and consumer health

Associate Director Site Engagement Leader - Oncology

Full-Time
$129.8k - $216.3k/yr

+ Annual bonus + Share-based long-term incentive program

Senior
Bachelor's
Remote in USA
Remote

Domestic travel of up to 60% is preferred.

About the job

Requirements
  • A bachelor's degree in life science or equivalent experience.
  • At least 5 years of experience in clinical research operations.
  • At least 3 years of experience in oncology clinical research.
Responsibilities
  • Contribute to the development of the Partnership Engagement and Excellence in Research Site Network and act as the main point of contact between GSK and sites.
  • Identify external organizations and institutions and evaluate their interest in building and developing local, national, or international networks with GSK.
  • Lead the development and expansion of institutions and sites by building and nurturing relationships across academic centers, community practices, and emerging site models.
  • Develop the GSK portfolio of clinical investigator sites through partnerships to attract more studies in the country, including coordination and oversight of partnership activities.
  • Provide feedback to leadership, Local Operating Company Medical Affairs, and the Local Operating Company regarding new partnerships and updates to existing partnerships.
  • Build and maintain trusted relationships with investigators, research coordinators, and site leadership.
  • Establish mutually agreed quality and performance key performance indicator targets, organize periodic performance reviews with external partners, track compliance with action plans, implement targeted solutions to reduce study cycle times, and optimize enrollment.
  • Participate in or lead site visits to provide targeted operational support and address site-specific challenges.
  • Work with sites and the Local Operating Company Clinical Operations Department to identify study- and site-level bottlenecks and risks to quality and compliance, and develop and implement mitigation plans and corrective actions.
  • Collaborate with planning and feasibility teams, Clinical Operations, and Medical Affairs to drive optimal site placement and study performance.
  • Lead or contribute to high-level country feasibilities for new therapeutic areas and support local feasibility activities.
  • Partner with cross-functional teams to optimize site activation timelines, including regulatory packets, budgets and clinical trial agreements, onboarding, and training.
  • Drive adoption of enterprise and centralized digital solutions such as electronic consent, electronic regulatory systems, remote site initiation visits, and electronic medical record-based identification and remote monitoring access.
  • Conduct ongoing environmental strategic surveillance and anticipate legislative and practical changes affecting sites and research in the country.
  • Use environmental insights to design and curate innovative and efficient partnerships.
  • Provide an operational vision of future GSK clinical research therapeutic areas and portfolio to key external stakeholders in collaboration with Local Medical Affairs.
  • Help research institutions and sites prepare for the arrival of clinical trials.
  • Provide strategic input for operational excellence, process efficiency, and trial delivery internally and externally.
  • Identify and share best practices with internal cross-functional process-improvement teams to optimize quality and productivity across local, regional, and global site networks.
Desired Qualifications
  • Ability to travel up to 60% domestically.
  • Experience in respiratory and/or hepatology.
  • Proficient knowledge of the drug development process.
  • Excellent understanding of the clinical study process, including monitoring.
  • Demonstrated track record of establishing and growing partnerships with strategic sites and institutions.
  • Strong client relationship and stakeholder management abilities.
  • Knowledge of and enthusiasm for digital solutions and technology, including experience helping others develop their digital and technology capabilities.
  • Experience designing, creating, and developing innovative ways of working across functions and with external partners.
  • Knowledge of industry trends and ability to anticipate the evolution of clinical research and propose strategic plans to optimize delivery.
  • Strong analytical and synthesis skills, including data storytelling.
  • Ability to anticipate, recognize, prevent, overcome, and resolve potential and current obstacles proactively.
  • Ability to help oneself, the team, and the business adapt positively to change.
  • Ability to acquire and maintain therapeutic-area and product knowledge across the GSK portfolio.
  • Agility in adapting to evolving strategic, operational, and pipeline landscapes.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • On September 1, 2026, GSK advanced its mRNA flu shot into Phase III.
  • HUTCHMED's September 4, 2026 deal adds HMPL-A830 for KRAS-altered colorectal, pancreatic, and lung cancers.
  • Q2 2026 sales rose 5% to £8.4 billion, and specialty medicines grew 14%.

What critics are saying

  • GSK will close Dresden by summer 2028, cutting 641 jobs and signaling flu overcapacity.
  • RBC downgraded GSK on September 8, 2026, after Q2 EPS guidance weakened from Nuvalent interest.
  • If mRNA flu disappoints against Moderna and Pfizer-BioNTech, GSK's vaccine edge erodes fast.

What makes GSK unique

  • GSK pairs vaccines scale with specialty medicines and a deep respiratory franchise.
  • Its mRNA flu program targets HA and NA, not HA alone.
  • The Noetik and HUTCHMED deals show disciplined external innovation, not pipeline vanity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Company News

Yahoo Finance
Sep 10th, 2026
GSK to close Dresden vaccine plant by 2028 after 115 years, cutting 650 jobs

Pharmaceutical company GlaxoSmithKline will close its vaccine production facility in Dresden, Germany by mid-2028, ending 115 years of operations. The site, which employs nearly 650 people, produces flu and hepatitis vaccines at a rate of 2 million doses weekly. GSK cited declining global demand and existing overcapacity as reasons for the closure. Future flu vaccine production will be consolidated at the company's facility in Ste-Foy, Canada. The Dresden plant was founded in 1911 by entrepreneur Karl August Lingner as the Saxon Serum Works. It was nationalised during East Germany's existence before British group SmithKline Beecham acquired it in 1992 following German reunification. The IG BCE trade union opposed the closure, warning that Saxony risks losing skilled industrial jobs and pharmaceutical production expertise.

Business Insider
Sep 8th, 2026
RBC Capital downgrades GlaxoSmithKline (GSK) to a Hold.

RBC Capital downgrades GlaxoSmithKline (GSK) to a Hold. Sep. 8, 2026, 06:07 PM RBC Capital analyst Trung Huynh downgraded GlaxoSmithKline to a Hold today and set a price target of £19.75. Huynh covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Pfizer. According to TipRanks, Huynh has an average return of 22.7% and a 75.69% success rate on recommended stocks. In addition to RBC Capital, GlaxoSmithKline also received a Hold from Bank of America Securities's Sachin Jain in a report issued on September 4. However, today, Barclays maintained a Sell rating on GlaxoSmithKline (LSE: GSK). Based on GlaxoSmithKline's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p8.41 billion and a net profit of p435 million. In comparison, last year the company earned a revenue of p7.99 billion and had a net profit of p1.44 billion Based on the recent corporate insider activity of 322 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year. Read More on GB:GSK:

Contract Pharma
Sep 4th, 2026
Hutchmed, GSK ink $1.3B cancer drug deal.

Hutchmed, GSK ink $1.3B cancer drug deal. GSK gains rights outside Greater China to develop HMPL-A830 for KRAS-altered tumors. September 4, 2026 Associate Editor, Contract Pharma Hutchmed Limited has entered into an exclusive development and license agreement with a subsidiary of GSK plc, giving the GSK subsidiary rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate that combines a highly selective KRAS small-molecule inhibitor payload with an anti-EGFR antibody. Initial clinical development will focus on colorectal, pancreatic and lung cancers. The agreement includes a $110 million upfront payment and up to $1.295 billion in potential development, regulatory and commercial milestone payments, plus royalties on net sales. Colorectal, lung and pancreatic cancers have among the highest incidence of KRAS-altered tumors, and patients often lack safe, durable KRAS-targeted therapies. HMPL-A830 is designed to deliver a KRAS inhibitor directly to EGFR-expressing tumors while blocking EGFR and KRAS signaling to improve efficacy, durability and tolerability. Hutchmed will lead the global phase I development program, expected to begin in the second half of 2026. GSK will handle subsequent clinical development and commercialization outside Mainland China, Hong Kong, Macau and Taiwan. "We are proud to work with GSK, a globally leading biopharmaceutical company that, like Hutchmed, is committed to developing innovative new cancer medicines to address significant unmet medical needs worldwide," said Johnny Cheng, Acting CEO and CFO of Hutchmed. "Our ATTCs combine antibodies with our proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action. HMPL-A830 is our third drug candidate from these novel payload platforms and the first from our platform to be licensed to a global partner, following two candidates that have entered clinical development. This collaboration marks a significant step in maximizing its potential as a treatment for patients, unlocking an entirely new class of precision oncology medicines." Dr. Hesham Abdullah, SVP, Global Head Oncology, R&D, GSK added, "The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care. We look forward to working with Hutchmed to progress this innovative asset through development."

Pharmaceutical Technology
Sep 3rd, 2026
HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy.

HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy. 3 September 2026 HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPL-A830, an investigational antibody-targeted therapy conjugate (ATTC) designed to target KRAS and EGFR in solid tumours. EGFR is an established driver of tumour growth in several solid cancers, including colorectal, pancreatic and non-small-cell lung cancers. It also plays an important role in resistance to KRAS-targeted treatments, particularly in colorectal cancer. Targeting both EGFR and KRAS is therefore intended to provide broader and more durable pathway inhibition. Under the agreement, GSK will receive worldwide development and commercialisation rights for HMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan. HUTCHMED will receive an upfront payment of US$110 million, along with potential development, regulatory and commercial milestone payments of up to US$1.295 billion and royalties on net sales. HMPL-A830 combines a selective KRAS small-molecule inhibitor with an antibody that targets the epidermal growth factor receptor (EGFR). The approach is designed to deliver the KRAS inhibitor directly to EGFR-expressing tumour cells while also blocking EGFR and KRAS signalling. The initial clinical development programme will focus on colorectal, pancreatic and lung cancers, which have high rates of KRAS alterations. KRAS mutations are particularly common in colorectal cancer, lung adenocarcinoma and pancreatic ductal adenocarcinoma. Despite recent advances in KRAS-targeted treatments, many patients, particularly those with KRAS mutations other than G12C, continue to have limited treatment options. Resistance to existing therapies and toxicities associated with broader KRAS and RAS inhibition also remain challenges. HUTCHMED will lead the global Phase I development programme for HMPL-A830, which is expected to begin in the second half of 2026. GSK will take responsibility for subsequent clinical development and commercialisation activities outside Mainland China, Hong Kong, Macau and Taiwan. The agreement marks HUTCHMED's first licensing deal with a global partner for an asset from its ATTC platform and expands GSK's oncology pipeline with a novel dual-targeting approach.

Finanzen.net
Sep 1st, 2026
GSK shares fall: mRNA flu vaccine advances to next study phase.

GSK shares fall: mRNA flu vaccine advances to next study phase. September 1, 2026, 11:12 a.m. GSK is making progress with the development of an mRNA-based flu vaccine. As the British pharmaceutical company announced, a late-stage study for the vaccine candidate will begin in September. In a mid-stage study with younger and older adults, the drug showed stronger immune responses compared with standard and high-dose flu vaccines, according to GSK. The vaccine was generally well tolerated. "Given one billion flu cases and up to 650,000 deaths worldwide each year, there is a need for next-generation vaccine approaches," said Sanjay Gurunathan, head of research and development for vaccines and infectious diseases at GSK. Messenger RNA is the technology that Moderna as well as Pfizer and BioNTech used to develop their Covid-19 vaccines. In trading on the London Stock Exchange, GSK shares were temporarily down 0.51 percent at 18.44 GBP. DJG/DJN/mgo/hab By Adria Calatayud Selected leveraged products on GSK. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on GSK. The base prospectus as well as the final terms and the basic information sheets can be obtained here: MM5AMJ, MM2M8P, MM18AM, MM2LN9, MM0WV7. Please also note the further information** regarding this advertisement. Risk warning: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.